Philippe Rochaix

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/592506/publications.pdf

Version: 2024-02-01

49 papers 3,313 citations

147801 31 h-index 214800 47 g-index

52 all docs 52 docs citations

times ranked

52

4935 citing authors

#	Article	IF	CITATIONS
1	Human Solid Tumors Contain High Endothelial Venules: Association with T- and B-Lymphocyte Infiltration and Favorable Prognosis in Breast Cancer. Cancer Research, 2011, 71, 5678-5687.	0.9	386
2	TNFî $_{\pm}$ blockade overcomes resistance to anti-PD-1 in experimental melanoma. Nature Communications, 2017, 8, 2256.	12.8	284
3	High endothelial venules (HEVs) in human melanoma lesions. Oncolmmunology, 2012, 1, 829-839.	4.6	161
4	Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. European Journal of Endocrinology, 2005, 152, 757-767.	3.7	160
5	CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics. Modern Pathology, 2012, 25, 1551-1558.	5.5	137
6	Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network. PLoS ONE, 2021, 16, e0246958.	2.5	131
7	High Endothelial Venule Blood Vessels for Tumor-Infiltrating Lymphocytes Are Associated with Lymphotoxin β–Producing Dendritic Cells in Human Breast Cancer. Journal of Immunology, 2013, 191, 2001-2008.	0.8	123
8	Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 155-160.	7.1	117
9	Indium-111–Pentetreotide Scintigraphy and Somatostatin Receptor Subtype 2 Expression: New Prognostic Factors for Malignant Well-Differentiated Endocrine Tumors. Journal of Clinical Oncology, 2008, 26, 963-970.	1.6	99
10	Identification of a New Panel of Serum Autoantibodies Associated with the Presence of <i>In situ</i> Carcinoma of the Breast in Younger Women. Clinical Cancer Research, 2009, 15, 4733-4741.	7.0	99
11	Signal transduction of somatostatin receptors negatively controlling cell proliferation. Journal of Physiology (Paris), 2000, 94, 205-210.	2.1	93
12	RCL2, a New Fixative, Preserves Morphology and Nucleic Acid Integrity in Paraffin-Embedded Breast Carcinoma and Microdissected Breast Tumor Cells. Journal of Molecular Diagnostics, 2006, 8, 157-169.	2.8	89
13	Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1. Nature Communications, 2020, 11, 437.	12.8	89
14	Stromal Estrogen Receptor-α Promotes Tumor Growth by Normalizing an Increased Angiogenesis. Cancer Research, 2012, 72, 3010-3019.	0.9	88
15	In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. Cancer Chemotherapy and Pharmacology, 2006, 57, 709-718.	2.3	86
16	Blocking Tumor Necrosis Factor α Enhances CD8 T-cell–Dependent Immunity in Experimental Melanoma. Cancer Research, 2015, 75, 2619-2628.	0.9	81
17	Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma. European Journal of Cancer, 2009, 45, 2316-2323.	2.8	76
18	Identification of biomarkers of human pancreatic adenocarcinomas by expression profiling and validation with gene expression analysis in endoscopic ultrasound-guided fine needle aspiration samples. World Journal of Gastroenterology, 2006, 12, 3344.	3.3	73

#	Article	IF	Citations
19	Value of cytokeratin $5/6$ immunostaining using D5/16ÂB4 antibody in the spectrum of proliferative intraepithelial lesions of the breast. A comparative study with $34^{12}E12$ antibody. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2003, 442, 548-554.	2.8	71
20	Pilot Study of Neoadjuvant Treatment with Erlotinib in Nonmetastatic Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2007, 13, 7086-7092.	7.0	68
21	PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells. JCI Insight, 2021, 6, .	5.0	64
22	Use and comparison of different internal ribosomal entry sites (IRES) in tricistronic retroviral vectors. BMC Biotechnology, 2004, 4, 16.	3.3	56
23	In vivo patterns of Bcl-2 family protein expression in breast carcinomas in relation to apoptosis., 1999, 187, 410-415.		54
24	Inhibition of Rho pathways induces radiosensitization and oxygenation in human glioblastoma xenografts. Oncogene, 2003, 22, 8861-8869.	5.9	53
25	PNL2, a New Monoclonal Antibody Directed against a Fixative-Resistant Melanocyte Antigen. Modern Pathology, 2003, 16, 481-490.	5.5	51
26	Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 281-287.	2.8	42
27	Childhood anaplastic large cell lymphoma Ki-1/CD30: Clinicopathologic features of 19 cases. Medical and Pediatric Oncology, 1994, 22, 155-161.	1.0	41
28	Statins Reduce Melanoma Development and Metastasis through MICA Overexpression. Frontiers in Immunology, 2013, 4, 62.	4.8	40
29	"Sugar―tumor of the pancreas: a rare entity that is diagnosable on preoperative fine-needle biopsies. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2005, 446, 555-559.	2.8	35
30	The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status. Cancer Gene Therapy, 2000, 7, 1543-1556.	4.6	34
31	KBA.62: a useful marker for primary and metastatic melanomas. Human Pathology, 2008, 39, 1136-1142.	2.0	34
32	Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 17769-17774.	7.1	33
33	Increased expression of a COOH-truncated nucleophosmin resulting from alternative splicing is associated with cellular resistance to ionizing radiation in HeLa cells. International Journal of Cancer, 2002, 100, 662-668.	5.1	32
34	Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy. Cancer Immunology Research, 2021, 9, 568-582.	3.4	30
35	Preclinical Toxicity, Toxicokinetics, and Antitumoral Efficacy Studies of DTS-201, a Tumor-Selective Peptidic Prodrug of Doxorubicin. Clinical Cancer Research, 2008, 14, 1258-1265.	7.0	27
36	Preclinical and Clinical Evidence that Deoxy-2-[18F]fluoro- <scp>D</scp> -glucose Positron Emission Tomography with Computed Tomography Is a Reliable Tool for the Detection of Early Molecular Responses to Erlotinib in Head and Neck Cancer. Clinical Cancer Research, 2010, 16, 4434-4445.	7.0	27

3

#	Article	IF	CITATIONS
37	Treatment of murine hepatocellular carcinoma using genetically modified cells to express interleukin-12. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, 388-396.	2.8	23
38	Adenoid cystic carcinoma of the lung: Interest of 18FDG PET/CT in the management of an atypical presentation. Lung Cancer, 2008, 59, 133-136.	2.0	18
39	Melanoma Cells Treated with GGTI and IFN- $\hat{1}^3$ Allow Murine Vaccination and Enhance Cytotoxic Response against Human Melanoma Cells. PLoS ONE, 2010, 5, e9043.	2.5	17
40	Two antiestrogens affect differently chromatin remodeling of trefoil factor 1 (pS2) gene and the fate of estrogen receptor in MCF7 cells. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2002, 1578, 12-20.	2.4	16
41	Breslow Thickness, Clark Index and Ulceration Are Associated with Sentinel Lymph Node Metastasis in Melanoma Patients: A Cohort Analysis of 612 Patients. Dermatology, 2014, 229, 183-189.	2.1	16
42	Dual Relief of T-lymphocyte Proliferation and Effector Function Underlies Response to PD-1 Blockade in Epithelial Malignancies. Cancer Immunology Research, 2020, 8, 869-882.	3.4	16
43	Is there an immunohistochemical technique definitively valid in epidermal growth factor receptor assessment?. Oncology Reports, 0, , .	2.6	11
44	An Alternative Fixative to Formalin Fixation for Molecular Applications: The RCL2®-CS100 Approach. Methods in Molecular Biology, 2011, 724, 297-307.	0.9	10
45	Macrocyclic Lactones Block Melanoma Growth, Metastases Development and Potentiate Activity of Anti–BRAF V600 Inhibitors. Clinical Skin Cancer, 2016, 1, 4-14.e3.	0.1	8
46	Prenylation inhibitors stimulate both estrogen receptor \hat{l}_{\pm} transcriptional activity through AF-1 and AF-2 and estrogen receptor \hat{l}^{2} transcriptional activity. Breast Cancer Research, 2004, 7, R60-70.	5.0	7
47	Gene expression profiling on pre―and postâ€erlotinib tumors from patients with head and neck squamous cell carcinoma. Head and Neck, 2013, 35, 809-818.	2.0	5
48	Preferential Cytoplasmic Localization of p34 cdc2 in Recurrent Human Squamous Cell Carcinoma after Radiotherapy. Radiation Research, 1997, 147, 277.	1.5	1
49	Les nouveaux fixateurs tissulaires. Revue Francophone Des Laboratoires, 2009, 2009, 25-32.	0.0	1